BRD-333 - Birdseye Therapeutics
A study of BRD-333 in Healthy Adult Participants (ANZCTR) - Oct 2, 2026 - P1 | N=40 | Not yet recruiting | Sponsor: Birdseye Therapeutics Inc 
First-in-human • New P1 trial • Immunology • Inflammation
https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12626001219370
 
Oct 2, 2026